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Abstract
Background: Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disease of the gastrointestinal
tract which includes ulcerative colitis and Crohn's disease. Genetic risk factors for IBD are not well understood.
Methods: We performed a family-based whole exome sequencing (WES) analysis on a core family (Family A) to
identify potential causal mutations and then analyzed exome data from a Caucasian pediatric cohort (136 patients
and 106 controls) to validate the presence of mutations in the candidate gene, heat shock 70 kDa protein 1-like
(HSPA1L). Biochemical assays of the de novo and rare (minor allele frequency, MAF < 0.01) mutation variant proteins
further validated the predicted deleterious effects of the identified alleles.
Results: In the proband of Family A, we found a heterozygous de novo mutation (c.830C > T; p.Ser277Leu) in
HSPA1L. Through analysis of WES data of 136 patients, we identified five additional rare HSPA1L mutations
(p.Gly77Ser, p.Leu172del, p.Thr267Ile, p.Ala268Thr, p.Glu558Asp) in six patients. In contrast, rare HSPA1L mutations
were not observed in controls, and were significantly enriched in patients (P = 0.02). Interestingly, we did not find
non-synonymous rare mutations in the HSP70 isoforms HSPA1A and HSPA1B. Biochemical assays revealed that all
six rare HSPA1L variant proteins showed decreased chaperone activity in vitro. Moreover, three variants demonstrated
dominant negative effects on HSPA1L and HSPA1A protein activity.
Conclusions: Our results indicate that de novo and rare mutations in HSPA1L are associated with IBD and
provide insights into the pathogenesis of IBD, and also expand our understanding of the roles of HSP70s in
human disease.
Keywords: Exome, Sequencing, Ulcerative colitis, Crohn's disease
Background
Inflammatory bowel disease (IBD) is a complex multifac-
torial disease that includes ulcerative colitis (UC) and
Crohn’s disease (CD). The etiology and pathogenesis of
IBD are incompletely understood, and treatment of IBD
can be difficult and is often unsuccessful. Although envir-
onmental factors likely play a significant role in the patho-
genesis of IBD, multiple twin cohort studies [1, 2] suggest
that genetic factors also contribute to IBD susceptibility.
Genome-wide association studies (GWASs) have identified
more than 163 risk loci for this disease [3–5] which include
NOD2, BACH2, IL23R, CARD9, and human leukocyte
antigen (HLA) loci. However, these common susceptibility
genes together only account for 13.6% of CD and 7.5% of
UC heritability [6]. One potential explanation for this herit-
ability gap is that GWASs typically evaluate common gen-
etic variants with minor allele frequency (MAF) > 0.05,
whereas rare variants (MAF < 0.01) are often not assessed
in these studies. Another likely reason for non-replication
of association signals is linkage disequilibrium (LD) differ-
ences and other environmental contributions in different
population groups [7].
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We previously reported a wide spectrum of rare and po-
tentially damaging variants in known IBD susceptibility
genes (excluding the HLA super-locus) identified through
whole exome sequencing analysis in eight patients with
pediatric IBD [8]. In the present study, we report a de
novo variant identified in the HSPA1L gene in a core
family (Family A), as well as further five additional rare
(MAF < 0.01), non-synonymous variants in this gene iden-
tified in a Caucasian cohort of 136 patients with pediatric
IBD. In contrast, rare non-synonymous mutations were
not observed in 106 controls. Moreover, we demonstrated
that all six de novo and rare variants had decreased refold-
ing activity in in vitro assays, with three of them showing
dominant negative effects.
HSPA1L, a member of the 70-kD heat shock protein
family (HSP70), is located within the HLA class III re-
gion 6p21, which has been reported as a risk locus for
IBD by GWASs on Indian and Japanese populations
[9, 10]. The HSP70 proteins play multiple roles in protein
quality control of the cell, including refolding denatured
proteins, preventing aggregation, and intracellular protein
transport. In addition, HSP70s have been shown to
modulate inflammatory response [11] and exert anti-
apoptotic functions [12] by inhibiting apoptosis regulat-
ing proteins, both of which are closely related to IBD
pathogenesis. However, the distinct role of each HSP70
family member is not well understood, and their poten-
tial role in IBD has not been established. Moreover,
clinically the expression of HSP70s was reported to be
unregulated in the intestine of patients with IBD [13].
Our study represents the first report on the association
between IBD and de novo and rare non-synonymous
mutations in the heat shock protein HSPA1L, thereby
demonstrating a functional role for this protein in IBD
and expanding our knowledge of the role of these pro-
teins in human disease.
Methods
Cases and samples
Written informed consent was provided by an attending
parent or legal guardian for pediatric participants. This
study was approved by the Institutional Review Boards of
Stanford University or the Southampton and South West
Hampshire Research Ethics Committee (REC) (09/H0504/
125) and University Hospital Southampton Foundation
Trust Research & Development (RHM CHI0497).
For Family A, the proband was diagnosed with UC at
the age of 16 and there was no family history of UC. A
summary of the patient phenotype and characteristics is
given in Table 1.
For the Soton pediatric inflammatory bowel disease
(PIBD) cohort, children diagnosed with PIBD were
recruited through University Hospital Southampton
(UHS). All children aged below 18 years at time of
diagnosis were eligible to join the study. Diagnosis was
established according to the Porto criteria, as previously
described [8]. Clinical data and venous blood samples
were collected. Parents and relatives diagnosed with IBD
were also routinely recruited.
Detailed patient clinical phenotypes are described in
Additional file 1.
Whole exome sequencing and data analysis
For Family A, whole exome sequencing and data analysis
were performed as previously described [14] with slight
modifications. In brief, whole exome enrichment was
Table 1 Summary of patient phenotypes and characteristics with HSPA1L mutation of interest
Sample ID HSPA1L mutation Age at diagnosis
(years)
Sex Disease Phenotype description Ethnicity Surgery Family
history
12 sa p.Ser277Leu (c.830C > T) 16 Female UC Initially left-sided colitis
and proctitis, subsequently,
pancolitis
Northern, Eastern
European, and
Middle-Eastern
mixed ancestry
- -
PR0034b p.Glu558Asp (c.1674A > T) 13 Male CD Nonstricturing ileocolonic White British + -
PR0142b p.Gly77Ser (c.229G > A) 13 Male UC Extensive mild to
moderate pancolitis;
maternal grandmother
has UC
Polish - +
PR0151b p.Ala268Thr (c.802G > A) 13 Female CD Panenteric colitis White British - -
PR0156b p.Thr267Ile (c.800C > T) 15 Male CD Terminal ileitis White British - -
PR0161b p.Ala268Thr (c.802G > A) 10 Female UC Extensive mild to moderate
pancolitis and autoimmune
sclerosing cholangitis; sister
has UC (Dx age 13 years)
White British - +
PR0244b p.Leu172del (c.515_517del) 13 Female IBDU Mild chronic inactive gastritis White British - -
UC ulcerative colitis, CD Crohn's disease, IBDU inflammatory bowel disease unclassified
aFrom Family A
bFrom IBD cohort
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performed with the Agilent SureSelect Human All Exon
V5 + UTRs kit (Agilent Technologies, Santa Clara, CA,
USA) and sequenced with the Illumina HiSeq 2000
sequencer (Illumina, San Diego, CA, USA). Paired-end,
101-b short reads generated from each library were
mapped to the reference genome hg19 with the
Burrows-Wheeler Aligner (version 0.7.7), and variants
were called with the Genome Analysis Toolkit [15]
(GATK; version 1.6-13-g91f02df ). Called single nucleo-
tide variants (SNVs) and Indel variants were further
annotated with ANNOVAR [16] (version 2013Aug23).
Potentially damaging Indels were predicted with the
Scale Invariant Feature Transform (SIFT) [17] (<0.05)
and PolyPhen-2 [18] (>0.85) algorithms.
For the PIBD cohort, whole exome capture was per-
formed using the Agilent SureSelect Human All Exon
51 Mb (versions 4 and 5) capture kit. Raw data generated
from paired-end sequencing protocols were aligned
against hg19 using Novoalign (novoalign/2.08.02) as previ-
ously described [8, 19]. Mapping steps produced parame-
ters for each sequenced position, such as base quality,
coverage, alternative allele, reference allele, and the num-
ber of reads at that position. Sequence coverage for each
sample was calculated with in-house customized scripts
that applied the BEDTools [20] package (v2.13.2). Sum-
mary statistics for each individual are listed in Additional
file 2. PICARD (picard/1.97) was used to remove duplicate
reads and SAMtools [21] mpileup (samtools/0.1.18) was
used to call single-nucleotide polymorphisms (SNPs) and
short Indels from the alignment file. Variations with read
depth <4 were excluded. Good-quality bases with a phred
score >20 were retained for downstream analysis [22, 23].
ANNOVAR (annovar/2013Feb21) [16] was applied for
variant annotation. A bespoke script was used to assign
individual variants as “novel” if they were not previously
reported in the dbSNP137 databases [24], 1000 Genomes
Project phase one (1KG) [25], the Exome Variant Server
(EVS) of European Americans of the NHLI-ESP project
with 6500 exomes (http://evs.gs.washington.edu/EVS/), in
46 unrelated human subjects sequenced by Complete
Genomics (46 CG) [26] or in the Southampton database
of reference exomes. Resultant variant files for each sub-
ject were subjected to further in-house quality control
tests to detect DNA sample contamination and ensure sex
concordance by assessing autosomal and X chromosome
heterozygosity. Variant sharing between all pairs of indi-
viduals was assessed to confirm that subjects were not re-
lated. Sample provenance was confirmed by application of
a validated panel developed specifically for exome data
[27]. Following our first process of high-quality variant de-
tection, FASTQ raw data for the PIBD cohort were further
analyzed to investigate the contribution of non-uniquely
mapped reads. These reads are considered poor quality
and usually discarded. However, it is possible that the
analysis of these reads might impact identification of SNPs
and Indels in highly homologous genes such as HSPA1L,
HSPA1A, and HSPA1B. The raw data generated from the
paired-end sequencing protocol were realigned against
hg19 using Novoalign with the option to report all align-
ment types. PICARD was not used to remove duplicate
reads, and any SNP or Indel was retained in the down-
stream analysis regardless of depth or phred score.
Variants in HSPA1L, HSPA1A, and HSPA1B
Information for all variants called in HSPA1L, HSPA1A,
and HSPA1B genes was collected for 136 PIBD patients
and 106 controls (Additional file 3).
Rare (MAF <0.01), non-synonymous HSPA1L muta-
tions were selected and verified by Sanger sequencing
in the proband and relatives where applicable (Fig. 1a,
Additional file 4).
Burden of mutation testing across HSPA genes
Whole exome sequencing data were available on 146
children diagnosed with IBD. The Soton analytical group
also has access to germline exome sequence data for 126
unrelated patients with no inflammatory-related disease.
In order to minimize bias for association analysis, we
conducted multidimensional scaling (MDS) analysis in
PLINK (plink/1.07) [28] on a combined set of patients
and controls and excluded non-Caucasian samples
(Additional file 5). This reduced the number of cases to
136 and controls to 106. All variants identified in any in-
dividual for HSPA1L, HSPA1A, and HSPA1B genes were
positively called in all samples across the PIBD patients
and controls, and these genotypes were selected for fur-
ther analysis.
To detect association between genetic variant and dis-
ease status, a gene-based test (the sequence kernel associ-
ation optimal unified test, SKAT-O [29]) was performed.
SKAT-O is used for the joint assessment of the contribu-
tion of rare and common variations within a genomic
locus with a trait [29]. Specifically, SKAT-O encompasses
both a burden test and a SKAT [29] test to offer a power-
ful way of conducting association analysis on combined
rare and common variations, as single variant tests are
often underpowered due to the large sample size needed
to detect a significant association.
In order to run the test, genotype information (homo-
zygous alternative, homozygous reference, or heterozy-
gous status) was retrieved using customized scripts
applying SAMtools [21], VCFtools [30], and BEDTools
[20] packages. All variant sites across the coding regions
of HSPA1L, HSPA1A, and HSPA1B genes were used to
generate a VCF file for each of the 136 cases and 106
unrelated, germline controls.
Variants were excluded using VCFtools [30] if they
deviated significantly from Hardy-Weinberg equilibrium
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status (P < 0.001) in the control group. VCF files con-
taining genotype information for all cases and controls
were merged and annotated.
To conduct the test, a group file of non-synonymous
and in-frame deletion only variants was created for each
of the three genes. SKAT-O was conducted excluding
synonymous variants, as these are less likely to impact
the protein function, as previously described [31–33].
SKAT-O was executed with the small sample adjust-
ment, by applying a MAF threshold of 0.01 to define
rare variations within the whole cohort, and using
default weights. The Efficient and Parallelizable Associ-
ation Container Toolbox for Sequence Data (EPACTS)
software package [34] was used to perform this test.
Expression of the HSPA1L protein
The HSPA1L gene consists of a single exon. The coding
region was amplified using genomic DNA from the
affected patient 12 s of Family A by PCR, and the PCR
products were cloned into a pCR-Blunt II-TOPO vector
(Invitrogen). After cloning, a common single nucleotide
variant rs2227956 was reverted to its reference sequence
(wild type, WT) by using a QuikChange II Site-Directed
Mutagenesis Kit (Agilent Technologies, La Jolla, CA,
USA), and p.Lys73Ser (c.218A >G, c.219A > C), p.Gly77-
Ser (c.229G >A), p.Leu172del (c.515-517del), p.Thr267Ile
(c.800C > T), p.Ala268Thr (c.802G > A), p.Ser277Leu
(c.830C > T), and p.Glu558Asp (c.1674A > T) mutants
were generated and subsequently cloned into the pGEX-
6P-1 vector (GE Healthcare, Waukesha, WI, USA) at the
BamHI-NotI restriction site. All sequences were con-
firmed by Sanger sequencing analysis at the Protein and
Nucleic Acid Facility (Stanford University).
The resulting vector was transformed into Escherichia
coli strain BL21 (New England Biolabs, Ipswich, MA,
USA), and recombinant fusion protein with a glutathione
S-transferase (GST) tag was expressed by induction with
0.1 mM of isopropyl-β-thiogalacto-pyranoside (Sigma) for
Fig. 1 De novo and rare variants in HSPA1L. a The pedigree and Sanger traces of Family A. The patient with ulcerative colitis (filled symbol) has a
de novo heterozygous mutation of c.830C > T (encoding p.Ser277Leu). b Schematic representation of the HSPA1L gene and de novo or rare
variants with the number of patients identified in Family A and 136 IBD cohort. Black, white, and gray circles represent ulcerative colitis, Crohn's
disease, and IBD unclassified, respectively. c The identified rare variants (left) on the structure of nucleotide binding domain (NBD) of HSPA1L (PDB
entry codes: 3GDQ [45]) and (right) on homology-based model of substrate binding domain (SBD) of HSPA1L created by using Phyre2 [46]. The
variant sites are shown in red, and ADP and PO4 are depicted as a space-filling representation in green. d Amino acid conservation of HSPA1L
among species. e Amino acid conservation among paralogs of HSPA1L in human. Amino acid sequences were aligned using Clustal Omega and
annotated using BOXSHADE (d, e)
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5–6 hours at 28 °C. Cells were pelleted and resuspended
in lysis buffer (50 mM pH7.5 Tris–HCl, 150 mM NaCl,
0.05% NP-40) and lysed with 0.25 mg/mL lysozyme (EMD
Millipore, Billerica, MA, USA) on ice for 30 minutes. The
samples were then sonicated and centrifuged at 20,000 × g
for 20 minutes. The resulting supernatants were incubated
with Glutathione Sepharose 4B beads (GE Healthcare) for
3 hours at 4 °C. Recombinant protein-bound beads were
subsequently washed with lysis buffer and incubated with
PreScission Protease (GE Healthcare) overnight at 4 °C.
Protein concentration was measured by Bradford assay.
The eluted protein was concentrated as necessary by using
Amicon Ultracel-3 K columns (Millipore). The purified
protein samples were aliquoted and stored at −80 °C.
In vitro chaperone assay
In vitro chaperone activity was measured with the HSP70/
HSP40 Glow-Fold Protein Refolding Kits (K-290, Boston
Biochem, Cambridge, MA, USA) according to the manu-
facturer’s protocol with modifications. In brief, recombin-
ant HSPA1L protein (4 μM), a 1:1 mixture of recombinant
HSPA1L WT protein (2 μM) and HSPA1L mutant pro-
tein, or a 1:1 mixture of HSPA1A protein (2 μM, Boston
Biochem) and recombinant HSPA1L protein (2 μM) was
used to test for refolding efficiency of heat-denatured
Glow-Fold Substrate protein. Luminescence measure-
ments were taken using a TECAN infinite 200 microplate
reader (TECAN Austria GmbH, Salzburg, Austria) at indi-
cated time points within 1 minute of mixing with luciferin
reagent. Refolding activity was calculated by subtracting
the luminescence at time 0 (before refolding reaction)
from that at 120 minutes (after refolding reaction). The
refolding activity of each control at 120 minutes was set as
100%. Data were compared between the control and test
samples using Dunnett's multiple comparison test.
Results
Family-based whole exome sequencing analysis revealed
a de novo mutation in HSPA1L
We analyzed the exomes of Family A, comprising the af-
fected proband (12 s) diagnosed with UC, both unaffected
parents, and an unaffected sibling. After excluding im-
plausible genes such as those encoding olfactory receptors
and mucins, and applying the in silico prediction algo-
rithms (SIFT < 0.05 and PolyPhen-2 > 0.85), we found a
single de novo heterozygous mutation, c.830C > T (encod-
ing p.Ser277Leu) affecting the gene HSPA1L only in 12 s
but not in the other family members (Fig. 1a, Table 1,
Additional file 6). All genotypes were confirmed by Sanger
sequencing (Fig. 1a). The mutation resides at a nucleotide
binding site (Fig. 1b and c) and is highly conserved be-
tween species (Fig. 1d) and within paralogous members of
the human HSP70 family (Fig. 1e). Other candidate genes
with homozygous or compound heterozygous deleterious
mutations were not evident from the SNV and Indel
variant calls (Additional file 6), thereby making HSPA1L
the lead candidate gene for the IBD phenotype.
Confirmation of additional rare mutations in HSPA1L in
larger cohort of patients with IBD
To determine the prevalence of rare HSPA1L mutations in
patients with IBD, we analyzed the exomes of an additional
136 IBD patients and 106 exomes of non-IBD control sub-
jects. We identified 14 HSPA1L variants across the exomes
of children diagnosed with IBD and controls (Table 2). Four
were rare (MAF <0.01) non-synonymous mutations and
one was a novel in-frame 3-base pair (bp) deletion, which
were found only in IBD patients. Of the remaining nine
variants, two were low frequency (MAF 0.01–0.05) non-
synonymous mutations, two were common (MAF >0.05)
non-synonymous variants, and five were synonymous.
Thus, the rare (MAF <0.01, p.Glu558Asp, p.Gly77Ser,
p.Ala268Thr, p.Thr267Ile) and novel(p.Leu172del) non-
synonymous variants were observed in cases only.
Of interest, the four rare non-synonymous mutations
(p.Gly77Ser, p.Thr267Ile, p.Ala268Thr, and p.Glu558Asp)
and the novel in-frame deletion (p.Leu172del) reside at
highly conserved residues throughout speciation and
human paralogs (Fig. 1d and e). The p.Gly77Ser and
p.Leu172del variants are adjacent to the nucleotide
binding site and in the beta sheet structure (http://www.
uniprot.org/uniprot/P34931) respectively; p.Thr267Ile and
p.Ala268Thr are located at a nucleotide exchange factor
binding domain, and p.Glu558Asp resides in a substrate
binding domain. These five variants were deemed to be of
highest functional interest and were verified by Sanger
sequencing in the probands and all relatives for whom
DNA was available (Additional file 4). The HSPA1L muta-
tion p.Ala268Thr was also confirmed in the patient’s af-
fected sister, who is also diagnosed with UC.
Together with the index family case, these results indi-
cate that five of six HSPA1L IBD mutations may affect
nucleotide binding or exchange.
Mutations in HSPA1A and HSPA1B
We also examined the highly homologous HSPA1A and
HSPA1B genes in the exome sequenced cohort.
Although HSPA1L is expressed at a low level in the in-
testine, HSPA1A and HSPA1B are abundantly expressed
in this tissue. We found two common synonymous
variants in HSPA1A and five synonymous variants in
HSPA1B, of which three were at low frequency (MAF
0.01–0.05) in the 1000 Genome Project (Additional file 7).
We also performed variant calling only on the reads
that are non-uniquely mapped to the HSPA1A and
HSPA1B as described in Methods. Nevertheless, we did
not find non-synonymous mutations in either of the
HSPA1A and HSPA1B homologs.
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Joint rare variant association test
We conducted a gene-based test for assessing the com-
bined association of coding novel, rare, and low frequency
mutations between affected and unaffected individuals
within the whole cohort. This analysis was limited to
variants most likely to impact protein function and dis-
counted synonymous changes. For HSPA1L, SKAT-O test-
ing was conducted on the four rare non-synonymous
mutations (p.Gly77Ser, p.Thr267Ile, p.Ala268Thr, and
p.Glu558Asp) and one novel in-frame deletion (p.Leu172-
del) (see Methods). The test showed a significant associ-
ation between HSPA1L variants and the IBD phenotype
(P = 0.024, Additional file 8). When the SKAT-O test
was repeated to include the two low frequency non-
synonymous mutations (p.Ala8Pro and p.Glu558Ala) in
addition to the five rare mutations, the association
remained significant (P = 0.034, Additional file 9). Since
we did not observe any non-synonymous variants in
HSPA1A and HSPA1B, we did not conduct the SKAT-O
test for these genes. Overall, these analyses indicate that
the rare mutations in HSPA1L are associated with IBD.
The fact that the majority of mutations reside in specific
domains (i.e., at nucleotide binding or exchange) further
suggests that these variants are not randomly associated
with IBD and likely to be causative mutations.
In vitro chaperone activity assays showed defective protein
function
In order to evaluate the effects of the rare non-synonymous
variants on chaperone function, we measured the refolding
of heat-inactivated luciferase substrate using recombinant
HSPA1L proteins. In vitro functional analyses revealed that
all six variants resulted in partial or complete loss of in vitro
HSPA1L chaperone activity compared with the WT control
(Fig. 2a). Among them, three variants (p.Gly77Ser,
p.Leu172del, and p.Ser277Leu) showed complete loss of ac-
tivity, of which two are located at or near the nucleotide
binding site.
The HSPA1L mutations were heterozygous in each pa-
tient. To evaluate whether the mutant alleles have domin-
ant negative effects on WT HSPA1L protein, we compared
the activity of a 1:1 mixture (molar) of WT and mutant
protein with the activity of HSPA1L WT alone. We also
measured the activity of the previously known loss-of-
function mutation p.Lys73Ser (equivalent to p.Lys71Ser
in HSPA1A [35]) as a control for the dominant negative
effect. As shown in Fig. 2b, the identified variants
(p.Gly77Ser, p.Leu172del, and p.Ser277Leu) each exhib-
ited dominant negative effects as did the positive
control (p.Lys73Ser), whereas p.Thr267Ile, p.Ala268Thr,
and p.Glu558Asp showed additive effects (i.e., reduced
activity). In addition, the three variants (p.Gly77Ser,
p.Leu172del, and p.Ser277Leu) also dominant negatively
suppress the activity of WT HSPA1A in a 1:1 mixture
(molar) of WT HSPA1A and mutant HSPA1L protein
(Fig. 2c), suggesting that these variants may affect the ac-
tivity of other HSP70 chaperone family proteins.
Discussion
In this exome sequencing study, two phases of analysis
were conducted. The first phase was a family-based ana-
lysis, which revealed a de novo, novel HSPA1L mutation
as a candidate potential causative mutation in the index
IBD patient with no family history of IBD. The second
phase was the validation analysis of rare HSPA1L muta-
tions using a moderate number of exomes from cases
and controls. In the validation study, five different novel
or rare non-synonymous variants were identified in 6
out of 136 patients with IBD, whereas no rare variants
were found in 106 controls. The large number of rare
variants observed in HSPA1L may also result from se-
lective pressure at the HSPA1L locus, which is sup-
ported by the gene-environment interaction model
underlying IBD. The rare HSPA1L mutations observed
in the Southampton cohort were inherited from un-
affected parents, which might indicate that a potential
cumulative effect from other genetic defects may act ei-
ther independently or together with HSPA1L to influ-
ence disease susceptibility.
Although the minor allele frequency for each of these
five variants is too low to assess its association to the
disease individually, a gene-based SKAT-O test revealed
a significant burden of mutation (P = 0.024) when asses-
sing non-silent rare variants observed in HSPA1L. The
association maintained significance when reassessed to
include all rare and low frequency variants (P = 0.034).
The HSPA1L gene is located in the MHC class III re-
gion, which is within the IBD3 locus, a known genetic
linkage region for both UC and CD [36]. Likewise, in
our study, rare HSPA1L mutations were observed both
in UC, CD, and IBDU patients (Fig. 1b). These data sug-
gest that HSPA1L might play a common pathogenic role
in IBD. HSPA1L is constitutively expressed, but its
expression is at a lower level compared to other mem-
bers of the HSP70 family, such as HSPA1A and HSPA1B
[37]. Although the distinctive role of each isoform and
the substrate protein specificity for each HSP70 family
member have not been well studied, it is reported that
each HSP70 has binding preferences to purified peptides
[38]. Also in a recent study, Hasson et al. demonstrated
that HSPA1L, and not HSPA1A, promotes translocation
of parkin to damaged mitochondria [39], which is required
for mitophagy, suggesting that HSPA1L has specific pro-
tein substrates and functions. Further analysis of IBD
phenotype, response to therapy, and histopathological data
of patients with or without HSPA1L mutation may lead to
a better understanding of disease mechanisms.
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Fig. 2 (See legend on next page.)
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Recently, homodimerization of HSP70 (or DnaK in E
coli) [40, 41] and its relevance with the protein function
[42] have been reported. One possible explanation of
IBD pathogenesis is that mutated HSPA1L protein per-
turbs the HSP70 chaperone system dominant negatively
by preventing the dimerization [40, 42] and blocks its
protective effects to stress in the colon, which results in
the loss of normal intestinal barrier function against in-
vasive bacteria or bacterial toxins [43]. In mice, Hspa1a
and Hspa1b double knockout mice were phenotypically
normal; however, when treated with dextran sulfate
sodium and exposed to oxidative stress, they exhibited
colitis [44]. Further studies using mice with the specific
HSPA1L mutations identified in patients with IBD will
improve our understanding of the pathogenesis of IBD.
Among the identified variants, p.Gly77Ser, p.Leu172del,
and p.Ser277Leu were more deleterious in that they
showed almost complete loss of function and significant
dominant negative effects in in vitro assays. This severity
is consistent with their low allele frequency (i.e., de novo
or novel) in the human population (Table 2). We hypothe-
sized that these deleterious variants might be associated
with more severe clinical observations, such as very early
onset of IBD or severe symptoms; however, no such
correlation was evident in our modest-sized group of
subjects. For example, patient 12 s with a severe p.Ser277-
Leu mutation had relatively late onset at age 16, whereas
patient PR0161, who had a less-deleterious p.Ala268Thr
mutation, was diagnosed at age 10 years. We speculate
that other genetic and/or environmental factors are likely
to contribute to disease severity.
It is remarkable to note that, unlike HSPA1L, non-
synonymous variants were not found in the HSPA1A or
HSPA1B genes (Additional file 7) given that HSP70 fam-
ily proteins are highly homologous in sequence. This
was assessed in two ways: First we mapped short reads
using conventional alignment tools as described in
Methods; however, we were unable to completely ex-
clude technical limitation in mapping reads to highly
homologous regions to detect variation within these
genes. Thus, we also processed the unmapped reads on
the genes and searched the rare non-synonymous mu-
tations extensively (see Methods). With this additional
effort, we could not find any rare non-synonymous mu-
tations in HSPA1A and HSPA1B, indicating that the
mutations in HSP70 are HSPA1L-specific. This result is
important both in further understanding of the patho-
genesis of IBD and in developing drug strategy for pa-
tients with IBD who harbor the HSPA1L mutations.
Through whole exome sequencing analysis of Family
A and Caucasian IBD cohorts, we found a statistically
significant association between IBD and rare mutations
in the HSPA1L gene. These variants caused loss of func-
tion of the HSPA1L protein to varying degrees, and
three of them also exhibited dominant negative effects
on the wild-type protein, which may in turn contribute
to the disease phenotype. The frequency of HSPA1L mu-
tations in our cohort (4.4%) is high enough that they
could potentially be used for the purpose of genetic risk
assessment. In addition, we believe that these findings
may provide insights into the pathogenesis and treat-
ment of IBD as well as the general role of HSP70 pro-
teins in human biology and disease. They can also
suggest new directions for the development of therapeu-
tics by inactivating HSPA1L activity in patients with a
dominant negative mutation.
Conclusions
Our results indicate that de novo and rare mutations in
HSPA1L are associated with IBD. These findings provide
insights into the pathogenesis and treatment of IBD, as
well as expand our understanding of the roles of HSP70s
in human disease.
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Fig. 2 Effects of the HSPA1L variants on HSP70/HSP40-mediated refolding heat-denatured luciferase. a Reactivation of heat-denatured luciferase
in the presence of each HSPA1L variant (4 μM). Luciferase activity in the presence of HSPA1L WT at 120 minutes was set as 100%. ** indicates
P < 0.01 for the comparison between HSPA1L WT and each variant by Dunnett’s test (n = 3–6). b Dominant negative effects of Gly77Ser,
Leu172del, and Ser277Leu in refolding activity of each HSPA1L variant (2 μM) in the presence of HSPA1L WT (2 μM). Refolding activity of
HSPA1L WT (2 μM) only was set as 100%. ** indicates P < 0.01 for the comparison between HSPA1L WT only and each variant by Dunnett’s test
(n = 3–6). c Dominant negative effects of Gly77Ser, Leu172del, and Ser277Leu in refolding activity of each HSPA1L variant (2 μM) in the presence of
HSPA1A WT (2 μM). Refolding activity of HSPA1A WT (2 μM) only was set as 100%. * or ** indicates P < 0.05 or P < 0.01, respectively, for the comparison
between HSPA1A WT only and each variant by Dunnett’s test (n = 3–4). The activity of the previously known mutation Lys73Ser was measured
as a positive control for loss-of-function and dominant negative mutant. The bars represent the standard deviation. Data are representative of
two independent experiments
Takahashi et al. Genome Medicine _#####################_ Page 9 of 11
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the index patient with ulcerative colitis (12 s). (DOCX 126 kb)
Additional file 7: HSPA1A and HSPA1B variants identified in patients wth
IBD and controls (no filtering applied). (DOCX 68 kb)
Additional file 8: Results of SKAT-O within HSPA1L using non-synonymous
and non-frameshift rare (MAF < 0.01) variants. (DOCX 49 kb)
Additional file 9: Results of SKAT-O within HSPA1L using non-synonymous
and non-frameshift variants, excluding common variants (MAF > 0.05).
(DOCX 51 kb)
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